#china-biotech
#china-biotech

[ follow ]

To Beat China at Drug Innovation, Big Pharma and Generics Need the Supreme Court to End This Patent Absurdity

The Federal Circuit's panel-dependent jurisprudence and the "after-arising technology" exception enable patent evergreening, undermining U.S. biopharma competitiveness versus China.

World news

fromAxios

3 months ago

China pharma deals threaten U.S. biotech

China is rapidly becoming a global leader in biotech, AI and chemistry, capturing rising licensing deals while U.S. research funding cuts risk ceding leadership.

[ Load more ]

#china-biotech#china-biotech

To Beat China at Drug Innovation, Big Pharma and Generics Need the Supreme Court to End This Patent Absurdity

China pharma deals threaten U.S. biotech

#china-biotech
#china-biotech